文献速递肝病

城市中心黑人与非黑人HIV感染成人的高丙型肝炎治愈率

High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center.
PubMed 文献 · Hepatology · 2017-10-11

研究分析了2014年2月至2016年3月在马里兰州巴尔的摩市一家城市诊所启动直接抗病毒药物(DAA)治疗的255例HCV/HIV合并感染患者,患者接受标准化HIV护士/药师支持。总体持续病毒学应答率为97%(95%CI 93-98),黑人为96%(95%CI 93-98),非黑人为97%(95%CI 83-99),无显著种族差异。结论认为在护士/药师依从性支持项目中,HCV治疗对HIV感染者高度有效。

要点

  • 255例HCV/HIV合并感染患者启动DAA治疗,总体持续病毒学应答率为97%(95%CI 93-98)。
  • 黑人持续病毒学应答率为96%(95%CI 93-98),非黑人为97%(95%CI 83-99),无显著差异。
  • 持续病毒学应答率不因注射吸毒史、酒精使用或精神疾病诊断而异。

核心结论

  • 在护士/药师依从性支持项目中接受治疗的HIV感染者,HCV治疗高度有效。
  • 这些结果提示种族和社会心理共病可能不是HCV消除的障碍。

研究设计与样本

  • 研究分析了2014年2月至2016年3月在马里兰州巴尔的摩市一家城市诊所启动DAA治疗的255例HCV/HIV合并感染患者。
  • 患者接受标准化HIV护士/药师支持以促进依从性,包括护士访视和电话呼叫。

主要发现

  • 中位年龄43岁,黑人占88%,男性占73%,有注射吸毒史者占69%,有危险酒精使用史者占45%,合并精神疾病诊断者占57%。
  • 中位CD4计数为577(四分位距397-820)个/mm³;97%正在接受抗逆转录病毒治疗,HIV RNA<20拷贝/mL者占87%,HCV基因1型占98%。
  • 超过60%有显著纤维化(纤维化-4指数评分1.45-3.25者占44%,>3.25[肝硬化]者占17%),30%有HCV治疗经历。
  • 大多数患者(91%)接受雷迪帕韦/索磷布韦(LDV/SOF)联合或不联合利巴韦林治疗,疗程12周。
  • 总体持续病毒学应答率为97%(95%CI 93-98),黑人96%(95%CI 93-98)vs 非黑人97%(95%CI 83-99),无显著种族差异;不因注射吸毒史、酒精使用或精神疾病诊断而异。

临床怎么用

  • 作者认为,种族和社会心理共病可能不是HCV消除的障碍。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Hepatitis C virus (HCV) cure rates have been similar in patients with and without human immunodeficiency virus (HIV) coinfection; however, in the ION-4 study, black patients treated with ledipasvir/sofosbuvir (LDV/SOF) were significantly less likely to achieve cure (90%) compared to nonblack patients (99%). There are limited real-world data on the effectiveness of oral direct-acting antivirals (DAAs) in predominantly minority HIV/HCV coinfected populations. We analyzed HCV treatment outcomes among 255 HCV coinfected patients initiating DAAs between February 2014 and March 2016 in an urban clinic in Baltimore, Maryland. To facilitate adherence, patients received standardized HIV nurse/pharmacist support, which included nurse visits and telephone calls. Median age was 43 years, 88% were black, 73% male, 69% had a history of injection drug use, 45% a history of hazardous alcohol use, and 57% a comorbid psychiatric diagnosis. Median CD4 count was 577 (interquartile range, 397-820) cells/mm3 ; most (97%) were on antiretroviral therapy, had HIV RNA <20 copies/mL (87%), and were infected with HCV genotype 1 (98%). Over 60% had significant fibrosis (Fibrosis-4 Index score 1.45-3.25 [44%] and >3.25 [17%, cirrhosis]) and 30% were HCV treatment experienced. The majority of patients received LDV/SOF with or without ribavirin (91%) and were treated for 12 weeks. Overall, the sustained virological response rate was 97% (95% confidence interval [CI], 93-98) and did not vary by race (black, 96% [95% CI, 93-98]; nonblack, 97%, [95% CI, 83-99]), history of injection drug use, alcohol use, or psychiatric diagnosis. CONCLUSION: HCV treatment was highly effective among HIV-infected patients who received care within an integrated nurse/pharmacist adherence support program. These results suggest that race and psychosocial comorbidity may not be barriers to HCV elimination. (Hepatology 2017;66:1402-1412).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Falade-Nwulia O, Sutcliffe C, Moon J, et al. High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center. Hepatology. 2017. PMID: 28608973. doi:10.1002/hep.29308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。